MMAP-13 TREATMENT MODALITIES AND SURVIVAL OUTCOMES IN NEUROENDOCRINE LUNG CANCER PATIENTS WITH BRAIN METASTASES: A REAL-WORLD ANALYSIS OF THE NATIONAL CANCER DATABASE

Abstract Brain metastases (BM) are a frequent and severe complication in neuroendocrine lung cancer (LCNEC), but data on treatment patterns and survival outcomes are limited. We analyzed the National Cancer Database (2010–2021) enrolling LCNEC patients with BM. Descriptive statistics, Kaplan-Meier survival analysis, and multivariable Cox regression were performed. Of 285,358 lung cancer patients, 41,514 (14.5%) had LCNEC with BM. BM incidence increased from 131 per 1,000 in 2010 to 162 per 1,000 in 2021. Median age was 66 years (IQR: 59.0-72.0); 50.5% were male and 54.1% had Medicare. Common primary tumor sites were upper lobe (45.2%), lower lobe (20.2%), and bronchus (9.2%). Small cell histology accounted for 86.2% of cases. Treatment distributions were systemic therapy with whole-brain radiotherapy (Sys+WBRT, 34.8%), systemic therapy only (29.7%), systemic therapy with stereotactic radiosurgery (Sys+SRS, 6.7%), and no treatment (17.7%). Median overall survival (OS) was longest with Sys+SRS (10.3 months), followed by Sys+WBRT (8.7 months) and systemic therapy alone (7.8 months). SRS only (2.9 months), WBRT only (2.0 months), and no therapy (1.3 months) were associated with inferior outcomes. Compared to Sys+SRS, multivariable Cox regression showed higher mortality with Sys+WBRT (HR 1.22, 95% CI 1.16–1.27, p<0.001), Sys only (HR 1.32, 95% CI 1.27–1.38, p<0.001), SRS only (HR 2.18, 95% CI 1.99–2.38, p<0.001), WBRT only (HR 3.14, 95% CI 2.98–3.30, p<0.001), and no treatment (HR 4.00, 95% CI 3.81–4.19, p<0.001). Worse OS was also independently associated with age ≥60 (HR 1.41, p<0.001), Medicaid (HR 1.04, p=0.024), uninsured status (HR 1.21, p<0.001), low education (HR 1.09, p<0.001), and comorbidity score ≥2 (HR 1.22, p<0.001). Multimodal treatment, especially Sys+SRS, offered the most favorable survival in LCNEC patients with BM. Age ≥60 years, Medicaid, uninsured status, lower education, and comorbidity score ≥2 was associated with inferior survival.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology Advances
Published
2025-08-01
DOI
https://doi.org/10.1093/noajnl/vdaf123.052
Primary Topic
Lung Cancer Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

MMAP-13 TREATMENT MODALITIES AND SURVIVAL OUTCOMES IN NEUROENDOCRINE LUNG CANCER PATIENTS WITH BRAIN METASTASES: A REAL-WORLD ANALYSIS OF THE NATIONAL CANCER DATABASE

Khalis Mustafayev, Fatma Nihan Akkoç Mustafayev, Rupesh Kotecha, Mohammad Arfat Ganiyani et al.
Neuro-Oncology Advances
Lung Cancer Research Studies
article

MMAP-13 TREATMENT MODALITIES AND SURVIVAL OUTCOMES IN NEUROENDOCRINE LUNG CANCER PATIENTS WITH BRAIN METASTASES: A REAL-WORLD ANALYSIS OF THE NATIONAL CANCER DATABASE

Khalis Mustafayev, Fatma Nihan Akkoç Mustafayev, Rupesh Kotecha, Mohammad Arfat Ganiyani, Zouina Sarfraz, Manmeet S. Ahluwalia, Yazmín Odia, Lindsey Spiegelman, Nicole T. Eiseler, Joseph Luzarraga
article en

Abstract

Abstract Brain metastases (BM) are a frequent and severe complication in neuroendocrine lung cancer (LCNEC), but data on treatment patterns and survival outcomes are limited. We analyzed the National Cancer Database (2010–2021) enrolling LCNEC patients with BM. Descriptive statistics, Kaplan-Meier survival analysis, and multivariable Cox regression were performed. Of 285,358 lung cancer patients, 41,514 (14.5%) had LCNEC with BM. BM incidence increased from 131 per 1,000 in 2010 to 162 per 1,000 in 2021. Median age was 66 years (IQR: 59.0-72.0); 50.5% were male and 54.1% had Medicare. Common primary tumor sites were upper lobe (45.2%), lower lobe (20.2%), and bronchus (9.2%). Small cell histology accounted for 86.2% of cases. Treatment distributions were systemic therapy with whole-brain radiotherapy (Sys+WBRT, 34.8%), systemic therapy only (29.7%), systemic therapy with stereotactic radiosurgery (Sys+SRS, 6.7%), and no treatment (17.7%). Median overall survival (OS) was longest with Sys+SRS (10.3 months), followed by Sys+WBRT (8.7 months) and systemic therapy alone (7.8 months). SRS only (2.9 months), WBRT only (2.0 months), and no therapy (1.3 months) were associated with inferior outcomes. Compared to Sys+SRS, multivariable Cox regression showed higher mortality with Sys+WBRT (HR 1.22, 95% CI 1.16–1.27, p<0.001), Sys only (HR 1.32, 95% CI 1.27–1.38, p<0.001), SRS only (HR 2.18, 95% CI 1.99–2.38, p<0.001), WBRT only (HR 3.14, 95% CI 2.98–3.30, p<0.001), and no treatment (HR 4.00, 95% CI 3.81–4.19, p<0.001). Worse OS was also independently associated with age ≥60 (HR 1.41, p<0.001), Medicaid (HR 1.04, p=0.024), uninsured status (HR 1.21, p<0.001), low education (HR 1.09, p<0.001), and comorbidity score ≥2 (HR 1.22, p<0.001). Multimodal treatment, especially Sys+SRS, offered the most favorable survival in LCNEC patients with BM. Age ≥60 years, Medicaid, uninsured status, lower education, and comorbidity score ≥2 was associated with inferior survival.

Neuro-Oncology AdvancesVol. 7(Supplement_2)
Baptist Hospital of Miami (US), Baptist Health South Florida (US), Dr. Herbert & Nicole Wertheim Family Foundation (US)
Good health and well-being
Openalex Percentile: Top 71%
Lung Cancer Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.